Our previous work demonstrated that SLAMF5 deficiency or antibody-mediated blockade delays disease onset and improves clinical outcomes in EAE, an animal model of MS, by modulating regulatory B cell function via the transcription factor c-MAF [36]. This evidence concerns the gene MAF and myeloid sarcoma.